{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"tesamorelin-nerve-damage","title":"Tesamorelin for Nerve Damage: Evidence Review","body":"## What's breaking down\nNerve damage often involves axonal disruption after injury, followed by slow or incomplete regeneration. Denervated muscle can atrophy over time because it receives no signals to maintain mass and strength. Repair pathways rely on growth factors and hormones that support axon regrowth and prevent wasting. When these signals stay low, functional recovery stalls even after surgical repair. Degeneration outpaces repair in many cases, leaving persistent sensory loss, weakness, or pain. Tesamorelin fits into discussions of the GH axis because it raises growth hormone levels, and GH has been linked in lab models to better axon regrowth and less muscle loss.\n\n## Why Tesamorelin might help you\n1. If your nerve injury leaves muscle without signals, GH elevation is discussed because animal work shows it can limit atrophy during the wait for reinnervation. 2. If axonal regrowth is the bottleneck, the same GH pathway is studied because it appears to support faster axon extension and better myelin thickness in rat models. 3. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain. It raises GH via the GHRH receptor, which in turn influences downstream factors tied to nerve and muscle maintenance.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. Tesamorelin targets the GH axis and its potential effects on visceral fat reduction alongside tissue repair signals. No other peptides are in scope here, so the discussion stays on how GH stimulation might intersect with nerve regeneration layers without overlapping essays on separate compounds.\n\n## What the evidence actually shows\nHuman data: One ongoing randomized, double-blinded, placebo-controlled Phase 2 trial (NCT03150511) tests tesamorelin after upper-extremity nerve repair. It started in 2018, remains recruiting as of late 2025, and has an estimated primary completion in 2027. No published results exist yet. The trial rationale rests on prior animal findings that GH improves nerve regeneration and functional recovery. Preclinical data: A 2019 rat study used systemic GH after chronic median-nerve denervation followed by nerve transfer. GH-treated rats showed higher axon density, larger axon diameter, thicker myelin, more reinnervated neuromuscular junctions, less muscle atrophy, and stronger grip recovery compared with untreated controls (preclinical tier). No completed human trials demonstrate tesamorelin efficacy for nerve damage. Approved human use of tesamorelin centers on visceral fat reduction in HIV patients, with secondary observations of muscle area and density changes in responders (human tier for that indication).\n\n## What scientists say\nResearchers at Johns Hopkins running the ongoing trial note that growth hormone has improved nerve regeneration and reduced muscle atrophy in animal models, forming the basis for testing tesamorelin in patients. They hypothesize faster motor and sensory recovery after surgical repair. Published reviews on peripheral nerve injury mention the trial as an example of growth-hormone-pathway exploration but do not cite outcome data because none are available.\n\n## What people say on Reddit\nAnecdotal reports mention hopes for post-surgical nerve growth but no clear personal confirmation of benefit after a cycle. Several users describe fluid-retention effects such as wrist aching, tingling, or carpal-tunnel-like symptoms while on tesamorelin; one linked these to elevated GH and resolved after stopping. Another reported reactive hypoglycemia requiring ER care shortly after starting. These are user experiences only and do not establish cause or efficacy for nerve repair.\n\n## What people say on X\nLimited public discussion appears on X specifically tying tesamorelin to nerve-damage outcomes. Searches surface general peptide conversations but no detailed case reports or outcome threads matching the scale of Reddit mentions.\n\n## What we do not know\nNo human efficacy data exist yet from the Phase 2 trial. Long-term effects on nerve recovery beyond the trial population remain untested. Whether GH elevation from tesamorelin translates to the same benefits seen with direct GH in rats is unknown. Individual responses, optimal timing relative to injury or surgery, and interactions with other conditions are not characterized in published human studies for this use.\n\n## Safety and limits\nTesamorelin carries known side effects including joint pain, fluid retention, and paresthesia in its approved indication. The same fluid-retention mechanism that can produce tingling or carpal-tunnel symptoms in some users is relevant when considering nerve-damage contexts. The ongoing trial monitors safety in post-injury patients, but final data are pending. All information here is for research review only; consult qualified medical professionals for personal health decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-nerve-damage/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"An ongoing Phase 2 randomized double-blinded placebo-controlled trial (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury, with estimated completion in 2027 and no results published as of late 2025.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current state of human evidence for the exact use case.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a 2019 rat study, systemic GH after chronic denervation and nerve transfer improved axon density, diameter, myelin thickness, neuromuscular junction reinnervation, reduced muscle atrophy, and grip strength recovery compared with controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the animal data cited as rationale for human testing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin is approved for visceral fat reduction in HIV patients and has shown increases in skeletal muscle area and density in treatment responders in secondary analyses of those trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human data on GH-axis effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report fluid-retention side effects including wrist pain, tingling, and in one case reactive hypoglycemia while using tesamorelin; one user hoped for post-surgery nerve growth but observed no clear benefit.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures user-reported experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. ... Recruiting ... Last Update Posted 2025-11-12 ... Primary Completion (Estimated) 2027-12","summary":"Ongoing Phase 2 trial details and status.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"c92fc5e450195b0494841a44ff38c7d3ef5ba07383cd288e70c209d50ef4a49c"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6395714/","title":"Growth Hormone Improves Nerve Regeneration, Muscle Re-Innervation, and Functional Outcomes After Chronic Denervation Injury","quote":"GH-treated animals demonstrated enhanced median nerve regeneration as measured by axon density (p < 0.005), axon diameter (p < 0.0001), and myelin thickness (p < 0.0001); improved muscle re-innervation ... reduced muscle atrophy ... greater recovery of motor function","summary":"2019 rat study on GH for nerve regeneration.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"c92fc5e450195b0494841a44ff38c7d3ef5ba07383cd288e70c209d50ef4a49c","hash":"46181b5b77988cd160f119bfdcb23367a43e773ed9529e13995640ac3c6999ac"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6766405/","title":"The Growth Hormone Releasing Hormone Analogue Tesamorelin Decreases Visceral Adipose Tissue...","quote":"Tesamorelin was associated with significantly greater increases in density of four truncal muscle groups ... and the lean ... muscles ... Significant increases were also seen in total area of the rectus and psoas muscles","summary":"Human data on muscle effects in HIV patients.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"46181b5b77988cd160f119bfdcb23367a43e773ed9529e13995640ac3c6999ac","hash":"14d3cb51f640124eb7184cf6521e90bb9e8b3e452a100e2566fd67f8c1f4f600"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"My primary goal was to see if I got any nerve growth 1-2 yrs post surgery, but I'm at the end of the cycle and there's just no way to tell","summary":"User anecdote on hoped-for nerve benefit.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"14d3cb51f640124eb7184cf6521e90bb9e8b3e452a100e2566fd67f8c1f4f600","hash":"254137c5bf9064c4092f297117134a000381e9248fd879a75d36b095d6939197"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1pjk16m/tesamorelin_possibly_sent_me_to_the_er/","title":"Tesamorelin possibly sent me to the ER","quote":"I became extremely dizzy, anxious, shaky ... blood sugar ... below 40 ... diagnosed with reactive hypoglycemia","summary":"User report of side effect.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"254137c5bf9064c4092f297117134a000381e9248fd879a75d36b095d6939197","hash":"7f4ca453e9421329c6c872f48863b97e6ccaeab65922672b0acf00c0085ab054"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:18:59.978Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Nerve Damage: Evidence Review","register":"source_ledger","body":"## What's breaking down\nNerve damage often involves axonal disruption after injury, followed by slow or incomplete regeneration. Denervated muscle can atrophy over time because it receives no signals to maintain mass and strength. Repair pathways rely on growth factors and hormones that support axon regrowth and prevent wasting. When these signals stay low, functional recovery stalls even after surgical repair. Degeneration outpaces repair in many cases, leaving persistent sensory loss, weakness, or pain. Tesamorelin fits into discussions of the GH axis because it raises growth hormone levels, and GH has been linked in lab models to better axon regrowth and less muscle loss.\n\n## Why Tesamorelin might help you\n1. If your nerve injury leaves muscle without signals, GH elevation is discussed because animal work shows it can limit atrophy during the wait for reinnervation. 2. If axonal regrowth is the bottleneck, the same GH pathway is studied because it appears to support faster axon extension and better myelin thickness in rat models. 3. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain. It raises GH via the GHRH receptor, which in turn influences downstream factors tied to nerve and muscle maintenance.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. Tesamorelin targets the GH axis and its potential effects on visceral fat reduction alongside tissue repair signals. No other peptides are in scope here, so the discussion stays on how GH stimulation might intersect with nerve regeneration layers without overlapping essays on separate compounds.\n\n## What the evidence actually shows\nHuman data: One ongoing randomized, double-blinded, placebo-controlled Phase 2 trial (NCT03150511) tests tesamorelin after upper-extremity nerve repair. It started in 2018, remains recruiting as of late 2025, and has an estimated primary completion in 2027. No published results exist yet. The trial rationale rests on prior animal findings that GH improves nerve regeneration and functional recovery. Preclinical data: A 2019 rat study used systemic GH after chronic median-nerve denervation followed by nerve transfer. GH-treated rats showed higher axon density, larger axon diameter, thicker myelin, more reinnervated neuromuscular junctions, less muscle atrophy, and stronger grip recovery compared with untreated controls (preclinical tier). No completed human trials demonstrate tesamorelin efficacy for nerve damage. Approved human use of tesamorelin centers on visceral fat reduction in HIV patients, with secondary observations of muscle area and density changes in responders (human tier for that indication).\n\n## What scientists say\nResearchers at Johns Hopkins running the ongoing trial note that growth hormone has improved nerve regeneration and reduced muscle atrophy in animal models, forming the basis for testing tesamorelin in patients. They hypothesize faster motor and sensory recovery after surgical repair. Published reviews on peripheral nerve injury mention the trial as an example of growth-hormone-pathway exploration but do not cite outcome data because none are available.\n\n## What people say on Reddit\nAnecdotal reports mention hopes for post-surgical nerve growth but no clear personal confirmation of benefit after a cycle. Several users describe fluid-retention effects such as wrist aching, tingling, or carpal-tunnel-like symptoms while on tesamorelin; one linked these to elevated GH and resolved after stopping. Another reported reactive hypoglycemia requiring ER care shortly after starting. These are user experiences only and do not establish cause or efficacy for nerve repair.\n\n## What people say on X\nLimited public discussion appears on X specifically tying tesamorelin to nerve-damage outcomes. Searches surface general peptide conversations but no detailed case reports or outcome threads matching the scale of Reddit mentions.\n\n## What we do not know\nNo human efficacy data exist yet from the Phase 2 trial. Long-term effects on nerve recovery beyond the trial population remain untested. Whether GH elevation from tesamorelin translates to the same benefits seen with direct GH in rats is unknown. Individual responses, optimal timing relative to injury or surgery, and interactions with other conditions are not characterized in published human studies for this use.\n\n## Safety and limits\nTesamorelin carries known side effects including joint pain, fluid retention, and paresthesia in its approved indication. The same fluid-retention mechanism that can produce tingling or carpal-tunnel symptoms in some users is relevant when considering nerve-damage contexts. The ongoing trial monitors safety in post-injury patients, but final data are pending. All information here is for research review only; consult qualified medical professionals for personal health decisions.","claims":[{"id":"c1","text":"An ongoing Phase 2 randomized double-blinded placebo-controlled trial (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury, with estimated completion in 2027 and no results published as of late 2025.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current state of human evidence for the exact use case.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a 2019 rat study, systemic GH after chronic denervation and nerve transfer improved axon density, diameter, myelin thickness, neuromuscular junction reinnervation, reduced muscle atrophy, and grip strength recovery compared with controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the animal data cited as rationale for human testing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin is approved for visceral fat reduction in HIV patients and has shown increases in skeletal muscle area and density in treatment responders in secondary analyses of those trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human data on GH-axis effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report fluid-retention side effects including wrist pain, tingling, and in one case reactive hypoglycemia while using tesamorelin; one user hoped for post-surgery nerve growth but observed no clear benefit.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures user-reported experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. ... Recruiting ... Last Update Posted 2025-11-12 ... Primary Completion (Estimated) 2027-12","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6395714/","title":"Growth Hormone Improves Nerve Regeneration, Muscle Re-Innervation, and Functional Outcomes After Chronic Denervation Injury","quote":"GH-treated animals demonstrated enhanced median nerve regeneration as measured by axon density (p < 0.005), axon diameter (p < 0.0001), and myelin thickness (p < 0.0001); improved muscle re-innervation ... reduced muscle atrophy ... greater recovery of motor function","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6766405/","title":"The Growth Hormone Releasing Hormone Analogue Tesamorelin Decreases Visceral Adipose Tissue...","quote":"Tesamorelin was associated with significantly greater increases in density of four truncal muscle groups ... and the lean ... muscles ... Significant increases were also seen in total area of the rectus and psoas muscles","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"My primary goal was to see if I got any nerve growth 1-2 yrs post surgery, but I'm at the end of the cycle and there's just no way to tell","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1pjk16m/tesamorelin_possibly_sent_me_to_the_er/","title":"Tesamorelin possibly sent me to the ER","quote":"I became extremely dizzy, anxious, shaky ... blood sugar ... below 40 ... diagnosed with reactive hypoglycemia","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":35735,"tokens_out":3185,"cost":0.05263125,"prev_hash":"genesis","hash":"0a818ac70d8016178f3ae10d7d68371602982091d66b54dbf70aaf5c3d5596ad"}],"provenance":[{"ts":"2026-06-29T23:18:59.978Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Nerve Damage\nSlug: tesamorelin-nerve-damage\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one pe","response":"{\n  \"slug\": \"tesamorelin-nerve-damage\",\n  \"title\": \"Tesamorelin for Nerve Damage: Evidence Review\",\n  \"body\": \"## What's breaking down\\nNerve damage often involves axonal disruption after injury, followed by slow or incomplete regeneration. Denervated muscle can atrophy over time because it receives no signals to maintain mass and strength. Repair pathways rely on growth factors and hormones that support axon regrowth and prevent wasting. When these signals stay low, functional recovery stalls even after surgical repair. Degeneration outpaces repair in many cases, leaving persistent sensory loss, weakness, or pain. Tesamorelin fits into discussions of the GH axis because it raises growth hormone levels, and GH has been linked in lab models to better axon regrowth and less muscle loss.\\n\\n## Why Tesamorelin might help you\\n1. If your nerve injury leaves muscle without signals, GH elevation is discussed because animal work shows it can limit atrophy during the wait for reinnervation. 2. If axonal regrowth is the bottleneck, the same GH pathway is studied because it appears to support faster axon extension and better myelin thickness in rat models. 3. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain. It raises GH via the GHRH receptor, which in turn influences downstream factors tied to nerve and muscle maintenance.\\n\\n## How these fit together\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. Tesamorelin targets the GH axis and its potential effects on visceral fat reduction alongside tissue repair signals. No other peptides are in scope here, so the discussion stays on how GH stimulation might intersect with nerve regeneration layers without overlapping essays on separate compounds.\\n\\n## What the evidence actually shows\\nHuman data: One ongoing randomized, double-blinded, place","tokens_in":35735,"tokens_out":3185,"cost":0,"prev":"genesis","hash":"ae92ddd7ac201fcad8229404583f2d6ee03184184a63745995dafa716d27ee9b"},{"ts":"2026-07-17T02:42:24.259Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-nerve-damage","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ae92ddd7ac201fcad8229404583f2d6ee03184184a63745995dafa716d27ee9b","hash":"79f378ca2f14f72cece708cdfb2510603a731f1faf79a60311b3d56a43eac46d"}],"energy":{"passes":2,"tokens_in":35735,"tokens_out":3185,"tokens_total":38920,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"79f378ca2f14f72cece708cdfb2510603a731f1faf79a60311b3d56a43eac46d"},"posted_at":"2026-06-29T21:33:33.704Z","created_at":"2026-06-29T21:33:33.704Z","updated_at":"2026-07-17T02:42:24.259Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-nerve-damage","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-nerve-damage","json":"https://miscsubjects.com/api/articles/tesamorelin-nerve-damage","bundle":"https://miscsubjects.com/api/articles/tesamorelin-nerve-damage/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-nerve-damage/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-nerve-damage","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-nerve-damage\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-nerve-damage\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-nerve-damage/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-nerve-damage\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-nerve-damage | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-nerve-damage","json":"/api/articles/tesamorelin-nerve-damage","markdown":"/api/articles/tesamorelin-nerve-damage/bundle?format=markdown","skill":"/api/articles/tesamorelin-nerve-damage/skill","topology":"/api/articles/tesamorelin-nerve-damage/topology","versions":"/api/articles/tesamorelin-nerve-damage/revisions","invocations":"/api/articles/tesamorelin-nerve-damage/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-nerve-damage","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"11599bdead353da236ad2151f21eefbf0eddfe72e8caeb14a73a9edd6ae80eb5","object":{"object_type":"article-object","identity":{"id":"article:tesamorelin-nerve-damage","slug":"tesamorelin-nerve-damage","title":"Tesamorelin for Nerve Damage: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/tesamorelin-nerve-damage","role":"explain","audience":"human"},"skill":{"route":"/api/articles/tesamorelin-nerve-damage/skill","role":"direct behavior","audience":"model","content":"---\nname: tesamorelin-nerve-damage\ndescription: Apply the Tesamorelin for Nerve Damage: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# Tesamorelin for Nerve Damage: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/tesamorelin-nerve-damage). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/tesamorelin-nerve-damage.\n- Read claims and relationships at /api/articles/tesamorelin-nerve-damage/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Nerve damage often involves axonal disruption after injury, followed by slow or incomplete regeneration. Denervated muscle can atrophy over time because it receives no signals to maintain mass and strength. Repair pathw\n\n## Representations\n\n- Human: /a/tesamorelin-nerve-damage\n- JSON: /api/articles/tesamorelin-nerve-damage\n- Relationships: /api/articles/tesamorelin-nerve-damage/topology\n- History: /api/articles/tesamorelin-nerve-damage/revisions\n"},"json":{"route":"/api/articles/tesamorelin-nerve-damage","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/tesamorelin-nerve-damage/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","tesamorelin","nerve","damage"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/tesamorelin-nerve-damage/invocations?status=success","failure_events":"/api/articles/tesamorelin-nerve-damage/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"tesamorelin-nerve-damage","title":"Tesamorelin for Nerve Damage: Evidence Review","body":"## What's breaking down\nNerve damage often involves axonal disruption after injury, followed by slow or incomplete regeneration. Denervated muscle can atrophy over time because it receives no signals to maintain mass and strength. Repair pathways rely on growth factors and hormones that support axon regrowth and prevent wasting. When these signals stay low, functional recovery stalls even after surgical repair. Degeneration outpaces repair in many cases, leaving persistent sensory loss, weakness, or pain. Tesamorelin fits into discussions of the GH axis because it raises growth hormone levels, and GH has been linked in lab models to better axon regrowth and less muscle loss.\n\n## Why Tesamorelin might help you\n1. If your nerve injury leaves muscle without signals, GH elevation is discussed because animal work shows it can limit atrophy during the wait for reinnervation. 2. If axonal regrowth is the bottleneck, the same GH pathway is studied because it appears to support faster axon extension and better myelin thickness in rat models. 3. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain. It raises GH via the GHRH receptor, which in turn influences downstream factors tied to nerve and muscle maintenance.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. Tesamorelin targets the GH axis and its potential effects on visceral fat reduction alongside tissue repair signals. No other peptides are in scope here, so the discussion stays on how GH stimulation might intersect with nerve regeneration layers without overlapping essays on separate compounds.\n\n## What the evidence actually shows\nHuman data: One ongoing randomized, double-blinded, placebo-controlled Phase 2 trial (NCT03150511) tests tesamorelin after upper-extremity nerve repair. It started in 2018, remains recruiting as of late 2025, and has an estimated primary completion in 2027. No published results exist yet. The trial rationale rests on prior animal findings that GH improves nerve regeneration and functional recovery. Preclinical data: A 2019 rat study used systemic GH after chronic median-nerve denervation followed by nerve transfer. GH-treated rats showed higher axon density, larger axon diameter, thicker myelin, more reinnervated neuromuscular junctions, less muscle atrophy, and stronger grip recovery compared with untreated controls (preclinical tier). No completed human trials demonstrate tesamorelin efficacy for nerve damage. Approved human use of tesamorelin centers on visceral fat reduction in HIV patients, with secondary observations of muscle area and density changes in responders (human tier for that indication).\n\n## What scientists say\nResearchers at Johns Hopkins running the ongoing trial note that growth hormone has improved nerve regeneration and reduced muscle atrophy in animal models, forming the basis for testing tesamorelin in patients. They hypothesize faster motor and sensory recovery after surgical repair. Published reviews on peripheral nerve injury mention the trial as an example of growth-hormone-pathway exploration but do not cite outcome data because none are available.\n\n## What people say on Reddit\nAnecdotal reports mention hopes for post-surgical nerve growth but no clear personal confirmation of benefit after a cycle. Several users describe fluid-retention effects such as wrist aching, tingling, or carpal-tunnel-like symptoms while on tesamorelin; one linked these to elevated GH and resolved after stopping. Another reported reactive hypoglycemia requiring ER care shortly after starting. These are user experiences only and do not establish cause or efficacy for nerve repair.\n\n## What people say on X\nLimited public discussion appears on X specifically tying tesamorelin to nerve-damage outcomes. Searches surface general peptide conversations but no detailed case reports or outcome threads matching the scale of Reddit mentions.\n\n## What we do not know\nNo human efficacy data exist yet from the Phase 2 trial. Long-term effects on nerve recovery beyond the trial population remain untested. Whether GH elevation from tesamorelin translates to the same benefits seen with direct GH in rats is unknown. Individual responses, optimal timing relative to injury or surgery, and interactions with other conditions are not characterized in published human studies for this use.\n\n## Safety and limits\nTesamorelin carries known side effects including joint pain, fluid retention, and paresthesia in its approved indication. The same fluid-retention mechanism that can produce tingling or carpal-tunnel symptoms in some users is relevant when considering nerve-damage contexts. The ongoing trial monitors safety in post-injury patients, but final data are pending. All information here is for research review only; consult qualified medical professionals for personal health decisions.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/tesamorelin-nerve-damage/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"An ongoing Phase 2 randomized double-blinded placebo-controlled trial (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury, with estimated completion in 2027 and no results published as of late 2025.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current state of human evidence for the exact use case.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a 2019 rat study, systemic GH after chronic denervation and nerve transfer improved axon density, diameter, myelin thickness, neuromuscular junction reinnervation, reduced muscle atrophy, and grip strength recovery compared with controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the animal data cited as rationale for human testing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin is approved for visceral fat reduction in HIV patients and has shown increases in skeletal muscle area and density in treatment responders in secondary analyses of those trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human data on GH-axis effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report fluid-retention side effects including wrist pain, tingling, and in one case reactive hypoglycemia while using tesamorelin; one user hoped for post-surgery nerve growth but observed no clear benefit.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures user-reported experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. ... Recruiting ... Last Update Posted 2025-11-12 ... Primary Completion (Estimated) 2027-12","summary":"Ongoing Phase 2 trial details and status.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"c92fc5e450195b0494841a44ff38c7d3ef5ba07383cd288e70c209d50ef4a49c"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6395714/","title":"Growth Hormone Improves Nerve Regeneration, Muscle Re-Innervation, and Functional Outcomes After Chronic Denervation Injury","quote":"GH-treated animals demonstrated enhanced median nerve regeneration as measured by axon density (p < 0.005), axon diameter (p < 0.0001), and myelin thickness (p < 0.0001); improved muscle re-innervation ... reduced muscle atrophy ... greater recovery of motor function","summary":"2019 rat study on GH for nerve regeneration.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"c92fc5e450195b0494841a44ff38c7d3ef5ba07383cd288e70c209d50ef4a49c","hash":"46181b5b77988cd160f119bfdcb23367a43e773ed9529e13995640ac3c6999ac"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6766405/","title":"The Growth Hormone Releasing Hormone Analogue Tesamorelin Decreases Visceral Adipose Tissue...","quote":"Tesamorelin was associated with significantly greater increases in density of four truncal muscle groups ... and the lean ... muscles ... Significant increases were also seen in total area of the rectus and psoas muscles","summary":"Human data on muscle effects in HIV patients.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"46181b5b77988cd160f119bfdcb23367a43e773ed9529e13995640ac3c6999ac","hash":"14d3cb51f640124eb7184cf6521e90bb9e8b3e452a100e2566fd67f8c1f4f600"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"My primary goal was to see if I got any nerve growth 1-2 yrs post surgery, but I'm at the end of the cycle and there's just no way to tell","summary":"User anecdote on hoped-for nerve benefit.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"14d3cb51f640124eb7184cf6521e90bb9e8b3e452a100e2566fd67f8c1f4f600","hash":"254137c5bf9064c4092f297117134a000381e9248fd879a75d36b095d6939197"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1pjk16m/tesamorelin_possibly_sent_me_to_the_er/","title":"Tesamorelin possibly sent me to the ER","quote":"I became extremely dizzy, anxious, shaky ... blood sugar ... below 40 ... diagnosed with reactive hypoglycemia","summary":"User report of side effect.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T23:18:59.509Z","link_status":"ok","quote_status":"unverified","prev":"254137c5bf9064c4092f297117134a000381e9248fd879a75d36b095d6939197","hash":"7f4ca453e9421329c6c872f48863b97e6ccaeab65922672b0acf00c0085ab054"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:18:59.978Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"Tesamorelin for Nerve Damage: Evidence Review","register":"source_ledger","body":"## What's breaking down\nNerve damage often involves axonal disruption after injury, followed by slow or incomplete regeneration. Denervated muscle can atrophy over time because it receives no signals to maintain mass and strength. Repair pathways rely on growth factors and hormones that support axon regrowth and prevent wasting. When these signals stay low, functional recovery stalls even after surgical repair. Degeneration outpaces repair in many cases, leaving persistent sensory loss, weakness, or pain. Tesamorelin fits into discussions of the GH axis because it raises growth hormone levels, and GH has been linked in lab models to better axon regrowth and less muscle loss.\n\n## Why Tesamorelin might help you\n1. If your nerve injury leaves muscle without signals, GH elevation is discussed because animal work shows it can limit atrophy during the wait for reinnervation. 2. If axonal regrowth is the bottleneck, the same GH pathway is studied because it appears to support faster axon extension and better myelin thickness in rat models. 3. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain. It raises GH via the GHRH receptor, which in turn influences downstream factors tied to nerve and muscle maintenance.\n\n## How these fit together\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. Tesamorelin targets the GH axis and its potential effects on visceral fat reduction alongside tissue repair signals. No other peptides are in scope here, so the discussion stays on how GH stimulation might intersect with nerve regeneration layers without overlapping essays on separate compounds.\n\n## What the evidence actually shows\nHuman data: One ongoing randomized, double-blinded, placebo-controlled Phase 2 trial (NCT03150511) tests tesamorelin after upper-extremity nerve repair. It started in 2018, remains recruiting as of late 2025, and has an estimated primary completion in 2027. No published results exist yet. The trial rationale rests on prior animal findings that GH improves nerve regeneration and functional recovery. Preclinical data: A 2019 rat study used systemic GH after chronic median-nerve denervation followed by nerve transfer. GH-treated rats showed higher axon density, larger axon diameter, thicker myelin, more reinnervated neuromuscular junctions, less muscle atrophy, and stronger grip recovery compared with untreated controls (preclinical tier). No completed human trials demonstrate tesamorelin efficacy for nerve damage. Approved human use of tesamorelin centers on visceral fat reduction in HIV patients, with secondary observations of muscle area and density changes in responders (human tier for that indication).\n\n## What scientists say\nResearchers at Johns Hopkins running the ongoing trial note that growth hormone has improved nerve regeneration and reduced muscle atrophy in animal models, forming the basis for testing tesamorelin in patients. They hypothesize faster motor and sensory recovery after surgical repair. Published reviews on peripheral nerve injury mention the trial as an example of growth-hormone-pathway exploration but do not cite outcome data because none are available.\n\n## What people say on Reddit\nAnecdotal reports mention hopes for post-surgical nerve growth but no clear personal confirmation of benefit after a cycle. Several users describe fluid-retention effects such as wrist aching, tingling, or carpal-tunnel-like symptoms while on tesamorelin; one linked these to elevated GH and resolved after stopping. Another reported reactive hypoglycemia requiring ER care shortly after starting. These are user experiences only and do not establish cause or efficacy for nerve repair.\n\n## What people say on X\nLimited public discussion appears on X specifically tying tesamorelin to nerve-damage outcomes. Searches surface general peptide conversations but no detailed case reports or outcome threads matching the scale of Reddit mentions.\n\n## What we do not know\nNo human efficacy data exist yet from the Phase 2 trial. Long-term effects on nerve recovery beyond the trial population remain untested. Whether GH elevation from tesamorelin translates to the same benefits seen with direct GH in rats is unknown. Individual responses, optimal timing relative to injury or surgery, and interactions with other conditions are not characterized in published human studies for this use.\n\n## Safety and limits\nTesamorelin carries known side effects including joint pain, fluid retention, and paresthesia in its approved indication. The same fluid-retention mechanism that can produce tingling or carpal-tunnel symptoms in some users is relevant when considering nerve-damage contexts. The ongoing trial monitors safety in post-injury patients, but final data are pending. All information here is for research review only; consult qualified medical professionals for personal health decisions.","claims":[{"id":"c1","text":"An ongoing Phase 2 randomized double-blinded placebo-controlled trial (NCT03150511) is testing tesamorelin for functional recovery after peripheral nerve injury, with estimated completion in 2027 and no results published as of late 2025.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes current state of human evidence for the exact use case.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"In a 2019 rat study, systemic GH after chronic denervation and nerve transfer improved axon density, diameter, myelin thickness, neuromuscular junction reinnervation, reduced muscle atrophy, and grip strength recovery compared with controls.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Provides the animal data cited as rationale for human testing.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Tesamorelin is approved for visceral fat reduction in HIV patients and has shown increases in skeletal muscle area and density in treatment responders in secondary analyses of those trials.","section":"What the evidence actually shows","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Documents established human data on GH-axis effects.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Reddit users report fluid-retention side effects including wrist pain, tingling, and in one case reactive hypoglycemia while using tesamorelin; one user hoped for post-surgery nerve growth but observed no clear benefit.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s4","s5"],"source_status":"sourced","why_material":"Captures user-reported experiences separate from trials.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:18:59.588Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT03150511","title":"Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury","quote":"The aim of this clinical trial is to evaluate the efficacy of tesamorelin as a therapy for peripheral nerve injuries. ... Recruiting ... Last Update Posted 2025-11-12 ... Primary Completion (Estimated) 2027-12","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6395714/","title":"Growth Hormone Improves Nerve Regeneration, Muscle Re-Innervation, and Functional Outcomes After Chronic Denervation Injury","quote":"GH-treated animals demonstrated enhanced median nerve regeneration as measured by axon density (p < 0.005), axon diameter (p < 0.0001), and myelin thickness (p < 0.0001); improved muscle re-innervation ... reduced muscle atrophy ... greater recovery of motor function","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6766405/","title":"The Growth Hormone Releasing Hormone Analogue Tesamorelin Decreases Visceral Adipose Tissue...","quote":"Tesamorelin was associated with significantly greater increases in density of four truncal muscle groups ... and the lean ... muscles ... Significant increases were also seen in total area of the rectus and psoas muscles","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"reddit","url":"https://www.reddit.com/r/Peptides/comments/1e4ai7g/tesamorelin_no_recomp_occurring/","title":"Tesamorelin - no recomp occurring","quote":"My primary goal was to see if I got any nerve growth 1-2 yrs post surgery, but I'm at the end of the cycle and there's just no way to tell","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1pjk16m/tesamorelin_possibly_sent_me_to_the_er/","title":"Tesamorelin possibly sent me to the ER","quote":"I became extremely dizzy, anxious, shaky ... blood sugar ... below 40 ... diagnosed with reactive hypoglycemia","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":35735,"tokens_out":3185,"cost":0.05263125,"prev_hash":"genesis","hash":"0a818ac70d8016178f3ae10d7d68371602982091d66b54dbf70aaf5c3d5596ad"}],"provenance":[{"ts":"2026-06-29T23:18:59.978Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Nerve Damage\nSlug: tesamorelin-nerve-damage\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one pe","response":"{\n  \"slug\": \"tesamorelin-nerve-damage\",\n  \"title\": \"Tesamorelin for Nerve Damage: Evidence Review\",\n  \"body\": \"## What's breaking down\\nNerve damage often involves axonal disruption after injury, followed by slow or incomplete regeneration. Denervated muscle can atrophy over time because it receives no signals to maintain mass and strength. Repair pathways rely on growth factors and hormones that support axon regrowth and prevent wasting. When these signals stay low, functional recovery stalls even after surgical repair. Degeneration outpaces repair in many cases, leaving persistent sensory loss, weakness, or pain. Tesamorelin fits into discussions of the GH axis because it raises growth hormone levels, and GH has been linked in lab models to better axon regrowth and less muscle loss.\\n\\n## Why Tesamorelin might help you\\n1. If your nerve injury leaves muscle without signals, GH elevation is discussed because animal work shows it can limit atrophy during the wait for reinnervation. 2. If axonal regrowth is the bottleneck, the same GH pathway is studied because it appears to support faster axon extension and better myelin thickness in rat models. 3. Therefore for you: If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain. It raises GH via the GHRH receptor, which in turn influences downstream factors tied to nerve and muscle maintenance.\\n\\n## How these fit together\\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile. Tesamorelin targets the GH axis and its potential effects on visceral fat reduction alongside tissue repair signals. No other peptides are in scope here, so the discussion stays on how GH stimulation might intersect with nerve regeneration layers without overlapping essays on separate compounds.\\n\\n## What the evidence actually shows\\nHuman data: One ongoing randomized, double-blinded, place","tokens_in":35735,"tokens_out":3185,"cost":0,"prev":"genesis","hash":"ae92ddd7ac201fcad8229404583f2d6ee03184184a63745995dafa716d27ee9b"},{"ts":"2026-07-17T02:42:24.259Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-nerve-damage","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"ae92ddd7ac201fcad8229404583f2d6ee03184184a63745995dafa716d27ee9b","hash":"79f378ca2f14f72cece708cdfb2510603a731f1faf79a60311b3d56a43eac46d"}],"energy":{"passes":2,"tokens_in":35735,"tokens_out":3185,"tokens_total":38920,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"79f378ca2f14f72cece708cdfb2510603a731f1faf79a60311b3d56a43eac46d"},"posted_at":"2026-06-29T21:33:33.704Z","created_at":"2026-06-29T21:33:33.704Z","updated_at":"2026-07-17T02:42:24.259Z","machine":{"shape":"article.machine/v1","slug":"tesamorelin-nerve-damage","kind":"article","read":{"human":"https://miscsubjects.com/a/tesamorelin-nerve-damage","json":"https://miscsubjects.com/api/articles/tesamorelin-nerve-damage","bundle":"https://miscsubjects.com/api/articles/tesamorelin-nerve-damage/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":4,"sources":5,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/tesamorelin-nerve-damage/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=tesamorelin-nerve-damage","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-nerve-damage\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"tesamorelin-nerve-damage\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/tesamorelin-nerve-damage/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"tesamorelin-nerve-damage\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/tesamorelin-nerve-damage | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/tesamorelin-nerve-damage","json":"/api/articles/tesamorelin-nerve-damage","markdown":"/api/articles/tesamorelin-nerve-damage/bundle?format=markdown","skill":"/api/articles/tesamorelin-nerve-damage/skill","topology":"/api/articles/tesamorelin-nerve-damage/topology","versions":"/api/articles/tesamorelin-nerve-damage/revisions","invocations":"/api/articles/tesamorelin-nerve-damage/invocations"},"editorial_review":null,"editorial_audit":{"slug":"tesamorelin-nerve-damage","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"11599bdead353da236ad2151f21eefbf0eddfe72e8caeb14a73a9edd6ae80eb5"}}}